Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2017-06-01
|
| Seri Bilgileri: | Blood Advances |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S2473952920302056 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|